Jazz Pharma gains Americas rights to defibrotide from Sigma-Tau

2 July 2014

Ireland-headquartered drugmaker Jazz Pharmaceuticals (Nasdaq: JAZZ) has signed a definitive agreement Pharmaceuticals with privately-held Italian drugmaker Sigma-Tau for rights to defibrotide in the USA and all other countries in the Americas.

Sigma-Tau holds rights to market defibrotide in the Americas under an agreement with Italy’s Gentium, which was acquired by Jazz last year for $1 billion.

Defibrotide is a novel product that is marketed by Jazz in the European Union under the name Defitelio for the treatment of severe hepatic veno-occlusive disease (VOD) in patients over one month of age undergoing hematopoietic stem cell transplantation (HSCT) therapy. In the USA, Jazz is working with the Food and Drug Administration on the regulatory pathway for submission of a New Drug Application for the potential approval of defibrotide to treat patients with severe VOD.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK